HOUSTON, May 17, 2019 /PRNewswire/ — Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today provided an update on its application for FDA clearance and addressed a recent anonymous article published on SeekingAlpha.com.

“We know there is a lot of focus on whether or not, and when, Soliton can achieve FDA clearance to market its new Rapid Acoustic Pulse (RAP) technology,” commented Dr. Chris Capelli, President and CEO of Soliton.  “So, we would like to provide some insight regarding where we stand in this process.  We submitted our request for marketing clearance, referred to as a “510(k),” in March of this year.  The targeted time period for review of a 510(k) application is 90 days.  This means we should be receiving feedback from the FDA before the end of this month.  Importantly, we have not been notified that our application must be converted to a “De Novo” process, the approval of which can take considerably longer to secure.  While we cannot be certain that our application will continue as a 510(k) or that our application will eventually be cleared, we are now cautiously optimistic that our RAP device could be cleared sooner than we have been estimating.”

Dr. Capelli continued, “While we normally don’t comment on matters relating to our stock price, we are aware that the posting of an article by an anonymous author on SeekingAlpha.com has coincided with a precipitous drop in our stock price.  Given that this article contains numerous misstatements of fact, we feel compelled to comment on the most egregious of those misstatements to ensure that investors are not further misled.  The following recites a few of the misleading claims made in this article, followed by the factual reality:

CLAIMED: Remeditex has dumped every position that it has filed that it held on sec.gov. And they were smart decisions, as they all turned out to be dogs and are trading at a fraction today of what they traded at when Remeditex had its position. Will Remeditex follow this pattern and dump its entire position of SOLY? We believe it will.

FACTUAL: Mr. Brett Ringle, President of Remeditex, responded, “This statement is patently false.  We continue to hold our positions in a number of publicly traded portfolio companies.  We believe strongly in the underlying science and ultimate potential of Soliton.  Our commitment to Soliton is evidenced by our investing over $27 million and having stuck by the Company throughout its existence.  In fact, we even participated in the IPO.  We always carefully analyze our portfolio companies and we are convinced that Soliton has a bright future and we will continue to be a part of that future.”

CLAIMED: The company is years from having an FDA approved product.

FACTUAL: We have said in our filings and press releases that we expect clearance of our device by end of this year. However, as described above, it appears that we may receive notice back from the FDA regarding our 510(k) application this month.  While we cannot be sure, we are cautiously optimistic that our device may be cleared sooner than the Company previously indicated.

CLAIMED: Right now, they don’t even have a finished product to submit to the FDA.

FACTUAL: Only fully engineered, tested and documented finished products can be successfully submitted for FDA clearance, which is what we have done.  Future generation products are intended to incorporate planned improvements. Our Generation 3 RAP device we expect to offer in our nationwide launch will have significant changes from the Generation 2 device that we intend to offer in our initial market launch, which in turn will have significant changes from the Generation 1 device we have submitted for FDA review and clearance. We expect the changes made to our device from Generation 1 to Generation 2 will necessitate the filing of an additional 510(k) before being launched. We cannot be certain that the changes we deem appropriate to make to the Generation 3 RAP device prior to the nationwide launch will not require another 510(k) filing.

CLAIMED: SOLY’s study results are only shown on its website, and not in a peer reviewed journal, which makes the data less legitimate.

FACTUAL: Our clinical trial results were peer reviewed and published via the American Society For Laser Medicine & Surgery (ASLMS), one of the most respected bodies in laser medicine. Our device was also awarded “Best in Show” by the ASLMS.

CLAIMED: Zimmer also recommends using ZWave for cellulite treatment. So, what exactly is new or original in SOLY’s RAP technology?

FACTUAL: Soliton’s RAP shockwaves are 50 times faster (rise and fall time of peak pressure wave), 10 times higher in pressure and 4 times faster in repetition rate (click this link to see a direct comparison of the two devices: https://www.soliton.com/acoustic-shockwave/) than Zimmer ZWave.  Eight patent families and 68 issued and pending patents distinguish the unique attributes of Soliton RAP that we believe make it unlike any other acoustic pulse device available.  The repetition rate combined with the rapid rise and fall times alone are carefully designed to exploit the relaxation time and susceptibility to shear waves of the cellular and other structures we target.  We are the only device we know of with this capability other than “focused” acoustic devices, which can’t cover enough area to be practical for indications like tattoo removal and cellulite reduction and can result in significant heat and pain.

Dr. Capelli concluded, “We would encourage investors to consider the source.  These misleading claims, which appear to have led to significant financial loss to some of our shareholders come from an anonymous source identified only as a short-seller, someone who stands to benefit by instilling fear in those who may not know better.  This is so egregious that we feel compelled to explore all potential options against the perpetrators, including legal and regulatory.  Regardless, long after this short-seller, who believes they face no consequences for their tortious misstatements, profits from those who are misled, we will continue to stand in the full light of day by our claims, cautions and actions.  For those who have not been misled, we thank you for you continued support and encouragement.  We believe firmly that Soliton has tremendous potential and we remain committed to realizing that potential on your behalf.”

About Soliton, Inc.

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to reduce the number of treatment visits to remove unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. Both products are investigational and are not available for sale in the United States.

For more information about the Company, please visit:  http://www.soliton.com

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Soliton’s acoustic shockwave device to receive marketing clearance from the FDA. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading “Item 1A. Risk Factors” in the Form 10-K for year ended December 31, 2018 we filed with the SEC and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.


This corporate profile is a paid advertisement and is provided for information purposes only; it should not be used as the basis for any investment decision. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the SEC) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. The information contained in this corporate profile is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them. This corporate profile has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in this corporate profile. Individuals should assume that all information in this corporate profile is not trustworthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing. As of May 9, 2019, Pre-IPO Buzz and Strikepoint Media have received total compensation of  Three-Hundred and twenty-five thousand dollars from Soliton, Inc. for the preparation, publication, and management of this corporate profile as well as other marketing and investor relations services. We anticipate receiving additional compensation up to the amount of five hundred thousand dollars for the duration of the campaign. Pre-IPO Buzz, Strikepoint Media, and its principals currently hold no shares in Soliton, Inc., but may buy or sell such shares at any time without notice. This compensation and position constitute a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.

Information contained in this corporate profile will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Readers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.

Statistical information, dollar amounts, and market size data was provided by the profiled company and related sources which we believe to be reliable. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided herein, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC and the Financial Industry Regulatory Authority (“FINRA”).